These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33480648)

  • 21. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
    Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
    Pittock SJ; Berthele A; Fujihara K; Kim HJ; Levy M; Palace J; Nakashima I; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Fujita KP; Armstrong R; Wingerchuk DM
    N Engl J Med; 2019 Aug; 381(7):614-625. PubMed ID: 31050279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
    Risitano AM; Perna F; Selleri C
    Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab.
    Kim MS; Prasad V
    JAMA Intern Med; 2020 Feb; 180(2):315-317. PubMed ID: 31657842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones.
    Mei M; Gupta R; O'Donnell M; Al Malki MM; Aldoss I; Ali H; Farol L; Snyder D; Forman SJ; Nakamura R; Khaled S
    Biol Blood Marrow Transplant; 2019 May; 25(5):e183-e185. PubMed ID: 30708188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
    Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
    Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab.
    Kulasekararaj AG; Risitano AM; Maciejewski JP; Notaro R; Browett P; Lee JW; Huang M; Geffner M; Brodsky RA
    Blood; 2021 Nov; 138(20):1928-1938. PubMed ID: 34314483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Lee JW; Kulasekararaj AG
    Expert Opin Biol Ther; 2020 Mar; 20(3):227-237. PubMed ID: 32011183
    [No Abstract]   [Full Text] [Related]  

  • 30. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab.
    Boonyasampant M; Weitz IC; Kay B; Boonchalermvichian C; Liebman HA; Shulman IA
    Transfusion; 2015 Oct; 55(10):2398-403. PubMed ID: 25989361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
    Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.
    Harder MJ; Höchsmann B; Dopler A; Anliker M; Weinstock C; Skerra A; Simmet T; Schrezenmeier H; Schmidt CQ
    Front Immunol; 2019; 10():1639. PubMed ID: 31379839
    [No Abstract]   [Full Text] [Related]  

  • 33. Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International Paroxysmal Nocturnal Hemoglobinuria Registry.
    Röth A; Araten DJ; Larratt L; Kulasekararaj AG; Maciejewski JP; Wilson A; Gustovic P; Kanakura Y
    Eur J Haematol; 2020 Nov; 105(5):561-570. PubMed ID: 32640047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.
    Peffault de Latour R; Fremeaux-Bacchi V; Porcher R; Xhaard A; Rosain J; Castaneda DC; Vieira-Martins P; Roncelin S; Rodriguez-Otero P; Plessier A; Sicre de Fontbrune F; Abbes S; Robin M; Socié G
    Blood; 2015 Jan; 125(5):775-83. PubMed ID: 25477495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
    Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T
    Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recurrent allograft C3 glomerulonephritis and unsuccessful eculizumab treatment.
    Kaartinen K; Martola L; Räisänen-Sokolowski A; Meri S
    Clin Immunol; 2018 Feb; 187():104-106. PubMed ID: 29097196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case of thrombotic micro-angiopathy after heart transplantation successfully treated with eculizumab.
    Morales E; Rabasco C; Gutierrez E; Praga M
    Transpl Int; 2015 Jul; 28(7):878-80. PubMed ID: 25712140
    [No Abstract]   [Full Text] [Related]  

  • 38. [Eculizumab as rescue therapy for lupus nephritis-related thrombotic microangiopathy].
    Fani FM; Patera A; Delsante M; Rossi GM; Manenti L; Landini S; Regolisti G; Fiaccadori E
    G Ital Nefrol; 2020 Jun; 37(3):. PubMed ID: 32530153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
    Notaro R; Sica M
    Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy.
    Gabr JB; Bilal H; Mirchia K; Perl A
    J Investig Med High Impact Case Rep; 2020; 8():2324709620947266. PubMed ID: 32757799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.